Exelixis, Inc. (LON:0IJO)
36.36
+1.55 (4.46%)
At close: Feb 21, 2025
Exelixis Revenue
In the year 2024, Exelixis had annual revenue of $2.17B USD with 18.49% growth. Exelixis had revenue of $566.76M in the quarter ending December 31, 2024, with 18.16% growth.
Revenue
$2.17B
Revenue Growth
+18.49%
P/S Ratio
n/a
Revenue / Employee
$1.89M
Employees
1,147
Market Cap
8.16B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.17B | 338.49M | 18.49% |
Dec 31, 2023 | 1.83B | 219.15M | 13.60% |
Dec 31, 2022 | 1.61B | 176.09M | 12.27% |
Dec 31, 2021 | 1.43B | 447.43M | 45.31% |
Dec 31, 2020 | 987.54M | 19.76M | 2.04% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 43.19B |
GSK plc | 31.38B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
Hikma Pharmaceuticals | 2.39B |
ConvaTec Group | 1.74B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Exelixis News
- 8 days ago - Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025 - Business Wire
- 9 days ago - Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit - Business Wire
- 10 days ago - Exelixis Inc (EXEL) Q4 2024 Earnings: EPS of $0.48 Beats Estimate, Revenue Hits $567 Million - GuruFocus
- 11 days ago - Exelixis: Cabozantinib Continues To Grow, Zanzalintinib Could Soon Follow - Seeking Alpha
- 11 days ago - Q4 2024 Exelixis Inc Earnings Call Transcript - GuruFocus
- 11 days ago - Exelixis (EXEL) Q4 2024 Earnings Call Transcript - The Motley Fool
- 11 days ago - Exelixis targets $5B Zanza sales by 2033 with multiple pivotal trials in progress - Seeking Alpha
- 11 days ago - Exelixis, Inc. (EXEL) Q4 2024 Earnings Call Transcript - Seeking Alpha